Study objective: The duration of action of several new nonsedative antihistamine preparations as assessed by skin and bronchial reactivity to histamine has still not been well established. The aim of the study was to evaluate the duration of effect of loratadine (10 mg) and terfenadine (120 mg) administered once a day for one week on cutaneous and inhaled reactivity to histamine by comparison with a placebo.
Study objective:
The duration of action of several new nonsedative antihistamine preparations as assessed by skin and bronchial reactivity to histamine has still not been well established. The aim of the study was to evaluate the duration of effect of loratadine (10 mg) and terfenadine (120 mg) administered once a day for one week on cutaneous and inhaled reactivity to histamine by comparison with a placebo.
Subjects: Twenty-four adult asthmatic subjects were included in a parallel group study that compared the duration of effect of two antihistamines and a placebo on cutaneous and inhaled reactivity to histamine.
Study design: Baseline cutaneous and inhaled reactivity (concentration causing a fall of 20 percent in F E V , [PC20]) to histamine was obtained on three consecutive days. Loratadine (10 mg), terfenadine (120 mg) and a placebo loratadine were administered daily for 1 week to 3 groups of subjects. The PC20 was measured at the end of the N ew antihistamine preparations, antagonists of the H1 receptors, have been developed in recent years. Several reports have documented that these agents are powerful in blocking skin reactivity to histamine as was reviewed by Simons and Simonsl and S i m o n~.~ The effect of these preparations on bronchial responsiveness to histamine, and even more significant, the duration of the effect, have been less well documented. Astemizole blocks the effects of histamine inhalation tests in human^.^ We recently showed that astemizole, a new antihistamine preparation, can have a prolonged effect on histamineinduced bronchial responsiveness, the mean duration being 42 days after a one-week course,-' although the duration is only 24 to 48 h after a single dose. 5 Magnussen and coworkers6 also showed that after a single dose of azelastine, another long-acting anti-H1 preparation, histamine provocation was b l t~k e d for more than 99 h in some subjects. Recommendations have been made for timing the cessation of rlsrlal This work was funded in part 1)). Schering Canada Inc.
Manr~script received April 13; revision accepted July 1. medication period, 3 days later, and weekly until PC20 returned to baseline value (upper limit of 2 SD from the mean baseline value).
Results:
The mean blocking duration on cutaneous reactivity for loratadine was 6.9 days and for terfenadine, 7.2 days. The mean duration of the blocking effect on PC20 histamine was 8.5 days for loratadine and 7.2 days for terfenadine. These figures were significantly longer than for the placebo.
Conclusion:
These data suggest that terfenadine and loratadine have a comparable blocking effect on reactivity to cutaneous and inhaled histamine. A daily dose taken for one week will result in a mean blocking effect of one week.
(Chest 1993; 103:777-81)
PCi?O=concentration causing a fall of 20 percent in FEV,; PEFR = peak expiratory flow rate medications before inhalation challenges with pharmacologic agents.; At the time (1975), it was suggested that anti-H1 receptor histamine antagonists b e stopped 48 h before histamine inhalation tests. However, these recommendations did not apply for antihistamine preparations that were developed in recent years.
To the best of our knowledge, the duration of the effect of loratadine (Claritin, Schering Inc.) and terfenadine (Seldane, Merrell Dow) on histamine inhalation is unknown. We think that further information on the duration of action of loratadine would be relevant since histamine inhalation tests are frequently performed. The use of loratadine and terfenadine is becoming more common, and recommendations for when to stop the medication before histamine testing should be established for recently introduced antihistamine preparations. We therefore assessed the effect and drlration of action of loratadine and terfenadine on histamineinduced broncht~onstriction, as compared with skin reactivity, in asthmatic subjects.
MATERIALS A N D ME'~HOI)S

Subjrcts
Twenty-seven adult p:itients were included in this study All met the criteria for the diagnosis of i~sthm:~ set or~t I , ! . the American Thoracic Societyx Twenty-font of them remained in a clinically stable state throughont the study according to the following indicators: (1) no change in need for medication; (2) no exposure to relevant allergens (except house dust); (3) no respiratory tract infection; (4) no ncwturnal awakenings due to asthma symptoms. Bn)nchtdilators were stopped within the interval recommended by the American Academy of Aller~y, 8 h before for inhaled $,-adrenergic agents and 48 h before for sustained-release theophylline derivatives.' Use of inhaled steroid preparations was kept constant. The study prottm)l was accepted by a Icwal ethics committee, and a written consent form was obtained from each subject taking part in the study.
Study Design
The study was a single-blind seven-day trial of loratadine, terfenadine and a placebo, assigned in random order to a total of 24 subjects (8 receiving terfenadine, 9 receiving loratadine, 7 receiving a placvh). The study design is summarized in Figure 1 . On the first three days (day 1, 2 and 3), suhjects underwent a histamine inhalation test. On day 3, after obtaining a fall in FEV, followed by spontaneous functional recovery (approximately 30 min), a methacholine inhalation test was performed. We selected subjects within a wide range of bronchial hyperrespnnsiveness. On days 4 to 10, the medication (terfenadine [120 mg]. loratadine [ l o mg] or placebo) was administered in the morning: for the group receiving terfenadine, 120 mg was given; for the group receiving placebo, placebo loratadine wa5 given; for the group receiving loratadine, 10 mg, was given. Subjects tahng the medication were advised not to describe the shape or ta5te of the medication to the technician performing the test. All medications were in sealed envelopes. Subjects were not familiar with the medications. The histamine test was repeated on the last day of medication (day 10) and then weekly until the concentration causing a fall of 20 percent in FEV, (PC20) retnrned to the upper limit of 2 SD from the mean PC20 histamine resnlts of the three baseline days. The methacholine inhalation test was also repeated on the last day of medication (day 10) and on the last visit to verib that it was reprnducihle, ie, within a 3.2-fold difference cnmpared with the first test.v This guaranteed that the s~~b j e c t s were in a clinically steady state throughout the study, since loratadine and terfenadine have no effect on 1)ronchial responsiveness to methacholine. The subjects were asked to keep a diary and recvrd the peak expiratory flow rate (PEFR) every morning and evening throughout the study before taking bronchodilator medication to further verify that their condition was stable. Histamine and methacholine tests were performed at the same time of the day (morning or afternoon), and timing remained cnnstant for each snbject throughout the study Skin prick tests to histamine were performed before and after the active medication was administered on every visit. The test was performed in triplicate. Histamine phosphate (1 mdml) was used, and the mean of two perpendicular wheal diameters was recorded. The mean daily result of the three tests was kept for analysis.
Assessment of Spiromety and Bronchial Responsiwness
After assessment of baseline spirometry including FEV, and forced vital capacity accnrding to the standards of the American Thoracic Society,"' subjects underwent a histamine-methacholine inhalation test. The test upas performed following the method of Cockcroft and mworkers as noted by Chai et a17 with a Wright nebulizer (output=0.14 mVmin) at tidal volume breathing for 2 min. The concentration of histamine and methacholine was progressively donbled from 0.03 to a maximum of 32 mdml.
Analysis of Results
Dose-response curves to histamine and methacholine were drawn on a noncurnr~lative logarithmic scale and the PC20 was interpolated on the crlrve. Logarithmic transformation of PC20 was kept for statistical analysis. The mean result of the three skin tests to histamine phosphate was analyzed. Reference values for FEV, and the ratio of FEV, to forced vital capacity were taken from Knudson ?Obtained on the third study day of the baseline peritd; geometric mean for PC20.
analysis of vari;~nce, with cnntrasts whenever appropriate (NewmanKeuls).
Baseline anthropometric, clinical, and functional results are shown in Table 1 . Seventeen of 24 subjects (71 percent) were atopic (at least one immediate skin reaction to 15 common inhalants with skin prick testing) and 19 (79 percent) were taking inhaled steroid preparations. Baseline FEV, was less than 80 percent predicted and the ratio of FEV, to forced vital capacity was less than 85 percent predicted" in 11 of 24 subjects (46 percent). The PC20 for histamine and methacholine as assessed on the third day of the baseline period was reproducible within a 3.2-fold difference in 22 of 24 subjects (92 percent), the exceptions being subjects 13 and 15.
Baseline FEV, remained constant throughout the study period (p>0.05), with only five subjects showing changes between 10 and 20 percent comparing the lowest with the highest FEV, value before the histamine test on any of the study days. The PC20 methacholine results also remained unchanged throughout the study period (p>0.05), with only two subjects (No. 12 and 20, Table 1) showing changes greater than a 3.2-fold difference comparing PC20 results on the third and final study days. Mean maximum variability in PEFR ([highest value any time -lowest value any timehighest value any time] x 100) was 27 (-+ 13) percent for placebo, 25 ( * 13) percent for loratadine, and 24 ( k 16) percent for terfenadine (p>0.05).
Individual results for the duration of the effect on cutaneous and bronchial responsiveness to histamine for each medication are listed in Table 2 . The mean duration of the blocking effect on cutaneous reactivity to histamine was equivalent for loratadine and terfenadine (close to seven days) (F= 2.7, 0.05 <p<O. 1). The between-subject variability was significant. Two of seven subjects taking the placebo showed a significant blocking effect as compared with five of nine subjects receiving loratadine and seven of eight subjects taking terfenadine (xZ= 5 . 4 ; degrees of freedom = 2; p = 0.07).
The mean duration of the blocking effect on bronchial responsiveness to histamine was 9 days for loratadine and 7 days for terfenadine, compared with no significant blocking effect for the placebo ( F = 9.2, p<0.001), the contrasts (Newman-Keuls, p<0.05) being significant between the placebo and loratadine, the placebo and terfenadine but not between loratadine and terfenadine. All subjects receiving loratadine and terfenadine showed some blocking effect ranging from 3 to 20 days. For the 17 subjects taking active medication, there was no significant difference in the duration of the blocking effect on cutaneous reactivity and bronchial responsiveness (paired Student's t test, t = 0.6, p>0.05) and these two parameters were not significantly related (r = 0.15, p>0.05). The PC20 methacholine was not significantly affected comparing baseline values with those obtained at the end of each of the treatment periods (p>0.05).
Antihistamines provide effective therapy for many allergic and nonallergic conditions. The new sustainedrelease anti-H1 antihistamines are now widely used, the most relevant advantages over short-acting standard antihistamines being their efficacy, longer duration of action and minimal side effects, especially on the central nervous system. Very few studies have examined the duration of the effect of the new antihistamine preparations on bronchial responsiveness to a commonly used agonist bronchoconstrictor agent, histamine. Results of these studies also can be difficult to interpret, since the duration of treatment with antihistamines varies from one study to the next. The results of a previous s t u d 9 showed that astemizole administered for 1 week has a significant blocking effect on histamine-induced bronchoconstriction that can last for a mean of 42 days.
The magnitude of this effect (changes in PC20 varying from a tenfold to greater than 100-fold difference) was comparable to what was found by Holgate and coworkers.I2 In a recent s t~d y ,~ we investigated the duration of the blocking effect of a single 10-mg dose of astemizole. We found that there was a blocking effect on bronchial responsiveness to histamine in a significant proportion of subjects. However, this blocking effect was short-lived, lasting for only 1 to 2 days, and it was not accompanied by a corresponding effect on cutaneous reactivity to histamine. In this study, using a similar design as for the previous study on a~temizole,~ we found that the duration of the blocking effect of loratadine and terfenadine administered for 1 week was shorter, since the mean duration was 7 to 8 days with a maximum of 20 days.
The design of the study was single-blinded because we did not have placebo preparations of terfenadine. However, we tried to circumvent the potential pitfalls of this design by selecting subjects who had not taken loratadine or terfenadine preparations before the study Moreover, the technician performing the nonspecific challenge was not informed about the shape or taste of the preparation by the subject who underwent the test.
Nineteen of the 24 subjects included in the study (79 percent) were taking inhaled steroid preparations. T h e dose of inhaled steroids was kept constant throughout the study It is unknown whether routine use of inhaled steroids could modlfy the duration of effect or oral antihistamine preparations. Although this seems unlikely, a similar study performed on asthmatic subjects not taking inhaled antiinflammatory preparations would answer this question.
Antihistamine preparations differ greatly in their suppression of skin reactivity to h i~t a m i n e .~~,~~ The mean duration of the effect of loratadine was found to vary from 4 to 7 days as compared with from 17 to 28 days for astemizole.I4 The magnitude of the blocking effect of the various new antihistamines (astemizole, loratadine, terfenadine, cetirizine) administered in a single dose also is highly variable as was shown by Simons and coworkers recently.I5 In this study, we also found great variability in the blocking effect of lorataDuration of Et(ect of Loratadine and Terfenadine (Lebrecque eta/) dine and terfenadine on skin reactivity to histamine. This large between-subject variability may explain why the differences in the blocking effect compared with the placebo were only borderline from the statistical point ofview. We also found that the duration of the blocking effect on bronchial responsiveness to histamine was not related to the duration of the blocking effect on skin reactivity. Similar discrepancies also were found in previous studies in which astemizole was t e~t e d .~,~
The results of this study have relevant clinical implications. Standard antihistamines usually are stopped 48 h before a histamine inhalation test.; Our results indicate that loratadine and terfenadine perhaps should be stopped for a much longer interval before histamine inhalation testing, at least when they are used on a daily basis for 1 week. No changes in PC20 methacholine could be observed. This might favor the use of methacholine over histamine for routine assessment of bronchial responsiveness since long-acting antihistamines are widely used and may interfere with the results of histamine inhalation tests for longer intervals. Furthermore, methacholine inhalation induces less severe side effects than histamine. 16 The role of antihistamine preparations in the treatment of asthma is still controversial as was reviewed recently1' Clemastine, another antihistamine, has been shown to have an acute bronchodilator effectlx but no benefit in long-term treatment of asthma could be found.lg Azelastine, another long-acting antihistamine, can block the immediate asthmatic response to allergen provocation t e~t i n g .~ Although this study was not aimed at examining the efficacy of loratadine and terfenadine in the treatment of asthma, PEFR and methacholine bronchial responsiveness were monitored and did not show any significant differences within the three groups of subjects. It is to be noted that the majority of our subjects (19 of A proper prospective study examining this point is required.
